No major surprises from Neurocrine presentation, says JPMorgan

JPMorgan analyst Anupam Rama reiterated an Overweight rating and $191 price target on Neurocrine (NBIX) following the company’s presentation at the 2025 JPMorgan Healthcare Conference. There were no major surprises in the presentation, highlighting recent Crenessity approval, though there was an increased focus on the breadth of the pipeline, the analyst tells investors in a research note. The firm added that, on the R&D side, the company noted one new medicine reaching the market every two years.